Zenas BioPharma, Inc. (ZBIO) Reports Wider Loss Q4 EPS Estimates by 16.8%

Zenas BioPharma, Inc. (ZBIO) reported Q4 2025 GAAP loss of $4.54 per share, missing analysts’ estimates. The company did not generate revenue for the quarter as it does not have any commercial products. Net loss for the quarter was $240.4 million.

Shares of the company traded at $24.04. on volume of 363,684. It has a market capitalization of $1.24 billion. Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies.

Also Read

S&P 500 futures fall after major averages rebound on easing oil prices: Live updates

Australia’s central bank raises rates again in knife-edge decision

This biotech is working on a GLP-1 pill that could be better than the Wegovy version

Plugin developed by ProSEOBlogger. Get free gpl themes.

A detailed analysis of Zenas BioPharma, Inc.’s quarter follows shortly on AlphaStreet.

This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.

The post Zenas BioPharma, Inc. (ZBIO) Reports a Net Loss for Q4 FY25 first appeared on Alphastreet.

Source link
#Zenas #BioPharma #ZBIO #Reports #Wider #Loss #EPS #Estimates